TCON Overview
Upcoming Projects (TCON)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (TCON)
-
Taking an in-depth look at Tracon’s novel treatment option for Wet AMD, DE-122 (TRC105 endoglin antibody formulation)
Ticker: TCON
Execute By: Feb 14, 2018
Upcoming & Overdue Catalysts (TCON)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TCON)
-
Phase 1 data of TRC105 + Opdivo in Non-small cell lung cancer (NSCLC) to be presented at IASLC 2019 February 20-23
Ticker: TCON
Occurred on: Jan 22, 2019 -
Phase 2 data of TRC105 for Renal Cell Carcinoma due June 2018
Ticker: TCON
Occurred on: Jun 13, 2018 -
Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017
Ticker: TCON
Occurred on: Jun 05, 2017 -
Tracon (TCON) Doses First Patient in Phase 3 TAPPAS Trial Evaluating TRC105 in Treatment of Angiosarcoma
Ticker: TCON
Occurred on: Feb 16, 2017 -
Tracon (TCON) Presents Phase 2 Data Evaluating TRC105 in Recurrent Glioblastoma (GBM)
Ticker: TCON
Occurred on: Feb 10, 2017 -
TRACON (TCON) Pharmaceuticals Announces Successful Meetings with FDA and EMA for TRC105 (carotuximab) in Angiosarcoma
Ticker: TCON
Occurred on: Oct 03, 2016 -
Tracon (TCON) Initiates Phase 1B Study Evaluating TRC105 in Patients with Lung Cancer
Ticker: TCON
Occurred on: Mar 14, 2016 -
TRACON Pharmaceuticals Announces Initiation of TRC102 Phase 2 Clinical Trial
Ticker: TCON
Occurred on: Jan 27, 2016 -
TRACON (TCON) Presents Positive Phase 1b Data for TRC105 + Inlyta at 2015 Kidney Cancer Association Meeting
Ticker: TCON
Occurred on: Nov 06, 2015
Strategic Initiatives (TCON)
-
TRACON (TCON) and Janssen (JNJ) Announce Strategic Licensing Collaboration for TRC253 in Treatment of Prostate Cancer and TRC694 in Treatment of Hematologic Malignancies
Tickers: JNJ, TCON
Announcement Date: Sep 28, 2016
